Final trial results of Kintor Pharmaceutical Ltd.’s Proxalutamide showed that the treatment could “significantly inhibit” the condition of male patients infected with Covid-19 changing from mild to severe, according to a company
The clinic trial included data from 134 male patients in the Proxalutamide group and 128 men in the control group. No patient given the drug was hospitalized, while 35 patients in the control group were hospitalized due to their condition worsening, the company said.
The company observed no adverse events related to Proxalutamide treatment, it added.
To contact Bloomberg News staff for this story:
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.